{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T11:56:52Z","timestamp":1769860612953,"version":"3.49.0"},"reference-count":51,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R231-A13800"],"award-info":[{"award-number":["R231-A13800"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Objective: To investigate the impact of neoadjuvant chemotherapy implementation with gemcitabine-cisplatin on survival outcomes for patients with muscle-invasive bladder cancer in Denmark.\nMaterials and Methods: Data were collected on all patients in Denmark undergoing radical cystectomy who were potential candidates for neoadjuvant chemotherapy from 2010 to 2015 (n = 851). A cohort before the implementation of neoadjuvant chemotherapy (Cohort 2010\u201312) was compared with a cohort after implementation (Cohort 2013\u201315). Patients in Cohort 2013\u201315 receiving neoadjuvant chemotherapy (+NAC, n = 213) were compared with patients in Cohort 2013\u201315 not receiving neoadjuvant chemotherapy (-NAC, n = 139). Pathological results after radical cystectomy and oncological outcomes were compared between the study cohorts. Overall survival, disease-free survival, and disease-specific survival were compared with Kaplan-Meier plots and with univariable and multivariable Cox regression. Kaplan-Meier estimates of overall survival were also performed separately for treating hospital and for pathological stage.\nResults: Pathological T0 (pT0) was more frequent in patients who received neoadjuvant chemotherapy: 34% versus 18% when comparing Cohort 2013\u201315 with Cohort 2010\u201312 (p &lt; 0.001), and 46% versus 16% in +NAC compared with -NAC (p &lt; 0.001). Overall survival, disease-free survival, and disease-specific survival at 5 years after cystectomy were not improved in Cohort 2013\u201315 compared with Cohort 2010\u201312 with adjusted hazard ratios of 1.11 (95% confidence interval [CI]: 0.87\u20131.43), 1.02 (95% CI: 0.81\u20131.29), and 1.06 (95% CI: 0.80\u20131.41), respectively.\nConclusions: This observational study found no improved survival in a national cohort of patients with muscle-invasive bladder cancer undergoing radical cystectomy after implementation of NAC. However, reservations should be made regarding the study design and the true effect of NAC on survival outcomes.<\/jats:p>","DOI":"10.2340\/sju.v59.24024","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T08:50:06Z","timestamp":1708937406000},"page":"39-46","source":"Crossref","is-referenced-by-count":3,"title":["DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer"],"prefix":"10.2340","volume":"59","author":[{"given":"Stefanie Korsgaard","family":"K\u00f6rner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Carus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Line Hammer","family":"Dohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulla Nordstr\u00f6m","family":"Joensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gitte Wrist","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels Viggo","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knud","family":"Fabrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thor Knak","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helle","family":"Pappot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads","family":"Agerb\u00e6k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rgen Bjerggaard","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"50173","doi-asserted-by":"crossref","unstructured":"Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859\u2013866.","DOI":"10.1056\/NEJMoa022148"},{"key":"50174","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa022148","DOI":"10.1056\/NEJMoa022148"},{"key":"50175","doi-asserted-by":"crossref","unstructured":"Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004;45(3):297\u2013303.","DOI":"10.1016\/j.eururo.2003.09.019"},{"key":"50176","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2003.09.019","DOI":"10.1016\/j.eururo.2003.09.019"},{"key":"50177","doi-asserted-by":"crossref","unstructured":"International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171\u20132177.","DOI":"10.1200\/JCO.2010.32.3139"},{"key":"50178","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2010.32.3139","DOI":"10.1200\/JCO.2010.32.3139"},{"key":"50179","doi-asserted-by":"crossref","unstructured":"Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: sum-mary of the 2020 guidelines. Eur Urol. 2021;79(1):82\u2013104.","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"50180","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"50181","doi-asserted-by":"crossref","unstructured":"Nguyen DP, Thalmann GN. Contemporary update on neoadjuvant therapy for bladder cancer. Nat Rev Urol. 2017;14(6):348\u2013358.","DOI":"10.1038\/nrurol.2017.30"},{"key":"50182","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nrurol.2017.30","DOI":"10.1038\/nrurol.2017.30"},{"key":"50183","doi-asserted-by":"crossref","unstructured":"Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer \u2018Unfit\u2019 for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432\u20132438.","DOI":"10.1200\/JCO.2011.34.8433"},{"key":"50184","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2011.34.8433","DOI":"10.1200\/JCO.2011.34.8433"},{"key":"50185","unstructured":"DaBlaCa. Nationale kliniske retningslinier for behandling af bl\u00e6retumorer i Danmark. [Cited 0 Nov. 2021] Available from: http:\/\/skejby.net\/Webudgaven\/Pdf\/DaBlaCa_april_2016.pdf"},{"key":"50186","unstructured":"DaBlaCa. Kliniske retningslinjer, behandling og opf\u00f8lgning af muskelinvasiv bl\u00e6rekr\u00e6ft (in Danish) 2020 [updated 2021 Oct 29]. [Cited 14 Nov. 2023] Available from: https:\/\/www.dmcg.dk\/siteassets\/kliniske-retningslinjer---skabeloner-og-vejledninger\/kliniske-retningslinjer-opdelt-pa-dmcg\/blarecancer\/dablaca_muskelinvasiv_1_1_admgodk111120.pdf"},{"key":"50187","doi-asserted-by":"crossref","unstructured":"Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol. 2012;61(6):1229\u20131238.","DOI":"10.1016\/j.eururo.2011.12.010"},{"key":"50188","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2011.12.010","DOI":"10.1016\/j.eururo.2011.12.010"},{"key":"50189","doi-asserted-by":"crossref","unstructured":"Petrelli F, Coinu A, Cabiddu M, et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol. 2014;65(2):350\u2013357.","DOI":"10.1016\/j.eururo.2013.06.049"},{"key":"50190","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2013.06.049","DOI":"10.1016\/j.eururo.2013.06.049"},{"key":"50191","doi-asserted-by":"crossref","unstructured":"K\u00f6rner SK, Jensen JB. A population-based retrospective analysis on variation in use of neoadjuvant chemotherapy depending on comorbidity in patients with muscle-invasive bladder cancer undergoing cystectomy in Denmark in the period 2013\u20132019. Scand J Urol. 2021; 56(1): 34\u201338.","DOI":"10.1080\/21681805.2021.2002400"},{"key":"50192","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2021.2002400","DOI":"10.1080\/21681805.2021.2002400"},{"key":"50193","doi-asserted-by":"crossref","unstructured":"Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551\u2013555.","DOI":"10.1038\/bjc.2013.725"},{"key":"50194","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/bjc.2013.725","DOI":"10.1038\/bjc.2013.725"},{"key":"50195","doi-asserted-by":"crossref","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u2013612.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"50196","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"50197","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020."},{"key":"50198","doi-asserted-by":"crossref","unstructured":"De Vocht F, Katikireddi SV, McQuire C, et al. Conceptualising natural and quasi experiments in public health. BMC Med Res Methodol. 2021;21(1):32.","DOI":"10.1186\/s12874-021-01224-x"},{"key":"50199","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12874-021-01224-x","DOI":"10.1186\/s12874-021-01224-x"},{"key":"50200","doi-asserted-by":"crossref","unstructured":"Jensen JB, Ulh\u00f8i BP, Jensen KM-E. Extended versus limited lymph node dissection in radical cystectomy: impact on recurrence pattern and sur-vival. Int J Urol. 2012;19(1):39\u201347.","DOI":"10.1111\/j.1442-2042.2011.02887.x"},{"key":"50201","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1442-2042.2011.02887.x","DOI":"10.1111\/j.1442-2042.2011.02887.x"},{"key":"50202","doi-asserted-by":"crossref","unstructured":"Nakagawa T. Lymph node dissection for bladder cancer: current standards and the latest evidence. Int J Urol. 2021;28(1):7\u201315.","DOI":"10.1111\/iju.14398"},{"key":"50203","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/iju.14398","DOI":"10.1111\/iju.14398"},{"key":"50204","doi-asserted-by":"crossref","unstructured":"Yin M, Joshi M, Meijer RP, et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist. 2016;21(6):708\u2013715.","DOI":"10.1634\/theoncologist.2015-0440"},{"key":"50205","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0440","DOI":"10.1634\/theoncologist.2015-0440"},{"key":"50206","doi-asserted-by":"crossref","unstructured":"Hanna N, Trinh QD, Seisen T, et al. Effectiveness of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the current real world setting in the USA. Eur Urol Oncol. 2018;1(1):83\u201390.","DOI":"10.1016\/j.euo.2018.03.001"},{"key":"50207","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euo.2018.03.001","DOI":"10.1016\/j.euo.2018.03.001"},{"key":"50208","doi-asserted-by":"crossref","unstructured":"Russell B, Sherif A, H\u00e4ggstr\u00f6m C, et al. Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival. Scand J Urol. 2019;53(4):206\u2013212.","DOI":"10.1080\/21681805.2019.1624611"},{"key":"50209","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2019.1624611","DOI":"10.1080\/21681805.2019.1624611"},{"key":"50210","doi-asserted-by":"crossref","unstructured":"M\u00f8ller CT, St\u00f8er NC, Blindheim A, et al. Downstaging and survival after Neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study. BMC Cancer. 2022;22(1):1301.","DOI":"10.1186\/s12885-022-10394-w"},{"key":"50211","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12885-022-10394-w","DOI":"10.1186\/s12885-022-10394-w"},{"key":"50212","doi-asserted-by":"crossref","unstructured":"Mitra AP, Cai J, Miranda G, et al. Management trends and outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder: evolution of the University of Southern California experience over 3,347 cases. J Urol. 2022;207(2):302\u2013313.","DOI":"10.1097\/JU.0000000000002242"},{"key":"50213","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/JU.0000000000002242","DOI":"10.1097\/JU.0000000000002242"},{"key":"50214","doi-asserted-by":"crossref","unstructured":"Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Sum-mary of the 2020 Guidelines. Eur Urol. 2021;79(1):82-104.","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"50215","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"50216","doi-asserted-by":"crossref","unstructured":"MRC\/EORTC. Neoadjuvant cisplatin,methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999;354(9178):533\u2013540.","DOI":"10.1016\/S0140-6736(99)02292-8"},{"key":"50217","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(99)02292-8","DOI":"10.1016\/S0140-6736(99)02292-8"},{"key":"50218","doi-asserted-by":"crossref","unstructured":"Pfister C, Gravis G, Flechon A, et al. Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG\/AFU V05 VESOER trial. JouJ Clin Oncol. 2023;41(17_suppl):LBA4507-LBA.","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4507"},{"key":"50219","doi-asserted-by":"crossref","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A, et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcita-bine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG\/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol. 2021;79(2):214\u2013221.","DOI":"10.1016\/j.eururo.2020.08.024"},{"key":"50220","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2020.08.024","DOI":"10.1016\/j.eururo.2020.08.024"},{"key":"50221","doi-asserted-by":"crossref","unstructured":"Holmsten K, Omland L, Als A, et al. Implications for efficacy and safety of total dose and dose-intensity of neoadjuvant gemcitabine-cisplatin in muscle-invasive bladder cancer: three-week versus four-week regimen. Bladder Cancer. 2021;8(1):71\u201380.","DOI":"10.3233\/BLC-211556"},{"key":"50222","doi-asserted-by":"crossref","unstructured":"Nielsen N, Wrist Lam G, Fabrin K, et al. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemo-therapy before radical cystectomy. Scand J Urol. 2019;53(4):213\u2013216.","DOI":"10.1080\/21681805.2019.1624608"},{"key":"50223","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2019.1624608","DOI":"10.1080\/21681805.2019.1624608"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/24024\/45424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/24024\/45424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T08:50:21Z","timestamp":1708937421000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/24024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":51,"URL":"https:\/\/doi.org\/10.2340\/sju.v59.24024","relation":{},"ISSN":["2168-1813","2168-1805"],"issn-type":[{"value":"2168-1813","type":"electronic"},{"value":"2168-1805","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,26]]}}}